No comments

Just for anybody’s who wants to comment on my blog : I am not confirming ANY comments on it I had too much spam messages and I don’t have time to see all comments which is good or spam … so I delate every day ALL COMMENTS send me

Sorry for your inconvenience but it’s like this

If you want to contact me ( not spam) send me mail:

svetpanuta@gmail.com

And I will see if it’s really professional mail or just a spam ( haw to create my blog and not about nerologie – all spam I put in garbage !!!)

My blog is free I am not gaining money from it I don’t have time for useless comments.

Thanks for understanding

Book /Livre

Voilà mon livre « Marc L’invincible » est désormais en ligne et disponible* à l’achat dans la boutique Kindle: ( en français)

https://www.amazon.fr/dp/B07Y34WPXQ

« Marc L’invincible: L’histoire vraie d’une récupération remarquable, après arrêt cardiaque et lésions cérébrales anoxiques », est désormais disponible en livre broché dans la boutique Amazon. Les lecteurs peuvent l’acheter:

https://www.amazon.fr/dp/B07Y4KC5S1

Here is my book « Marc L’invincible » is now online and available * for purchase in the Kindle store: (in French)

I will do English translation ( just give me some time)

Ici lien vers page de Écrivain-biographe basée à Grenoble -Membre des Compagnons Biographes – Julie Lucquet qui à prêter son plume pour raconter notre histoire :

https://www.facebook.com/298833463857319/posts/670782633329065?sfns=mo

Cord blood or MSC ?

Just 2 very interesting studies :

1) « behavioural deficit was significantly improved with multiple doses of cord blood, but not with a single dose. We also showed that the injury caused significant loss of brain tissue and cell death, which was only improved in the study arm that administered multiple doses of cord blood cells. “

Article:

https://parentsguidecordblood.org/en/news/multiple-doses-cord-blood-are-better-cerebral-palsy-animal-model

And second :

2) This was made on animal model but UCB seems to be batter choice than MSC….

So a lot to think….

« This study is the first to compare the neuroprotective efficacy ofUCB cells versus MSCs for inflammation-induced preterm braininjury. Both UCB cells and MSCs have protective benefits for thepreterm brain, but their effects on white matter are different.MSCs were strongly anti-inflammatory, dampening multipleindices of brain inflammation at the cellular and gene level. Incontrast, UCB cells showed a reduced ability to mediateneuroinflammation, but importantly, prevented apoptosis-mediated cell death and protected mature myelinating oligoden-drocytes. These differential effects of UCB and MSCs are likely dueto specific actions of an isolated cell population (MSCs) versus astem/progenitor cell mix (UCB). «

https://www.researchgate.net/publication/331658814_Umbilical_cord_blood_versus_mesenchymal_stem_cells_for_inflammation-induced_preterm_brain_injury_in_fetal_sheep

« CONCLUSION

In response to LPS-induced preterm brain injury, administration of

MSCs had a global effect on dampening brain inflammation,

which in turn may have detrimental effects on brain repair and

normal development. MSCs did not improve survival of critical

oligodendrocytes and did not prevent apoptosis-mediated cell

death. In contrast, UCB was neuroprotective against cell death and

normalized the number of mature myelinating oligodendrocytes, but did not display the same anti-inflammatory effects as MSCs.

Our results indicate that UCB is a more comprehensive therapy for

protecting white matter brain development, likely contributed by

the mixed cell population in UCB, and their differential actions. »

thé problème i think we need be very careful with dosing MSC:

« In contrast, MSCs require expansion by tissue culture

and are a much larger cell (average 25 μm), limiting the

concentration that can be administered in a single dose without

risk of embolism. »

And

« Therefore, a global dampening of inflammatory mediators with MSC administration (as seen in the directional change of the bars

in Fig. 4) may interrupt normal brain development and it may be

such that reducing an aberrant pro-inflammatory cerebral

response with cell treatment is preferable. MSC treatment

decreased white matter expression of IGF-1, which is essential

for normal oligodendrocyte maturation produced by multiple cell

types within the CNS, particularly the glial cells.

Indeed, IGF-1 is

proposed as a rescue therapy for hypomyelination,

and protective for oligodendrocytes. »

« The dampening of inflammation and growth factor expression

by MSCs may be a concern, further investigation into this finding

is required. »

Here’s the video of Dr. Kurtzberg speaking at the New Horizon Arizona Stem Cells conference -April 2019

Here’s the video of Dr. Kurtzberg speaking at the New Horizon Arizona Stem Cells conference :

(April 2019)

https://www.facebook.com/1115496706/posts/10218506814957717?s=1115496706&v=i&sfns=mo

7:30mins discuss male cells getting into brain of CP

Hydrocortisone reduces fevers

12mins starts to talk about autism

19mins only male donors for the cord tissue trial are being used but doesn’t mention if male are better than female. Taken from c-section babies (interesting as c-section implies potential complications). They expand the cells to passage 2. Each cord produces about 60billion expanded cells, amounting to 60 to 100 doses (@ 2million cells per kilo).

23mins one child didn’t use Benadryl and started coughing from transfusion, resolved with the use of Benadryl.

25:40mins hypoxic brain injury helped with cord blood. But beneficial effects stopped when CD14 cells are removed!

33mins slide with cell characteristics for CP trial.

36mins gross motor improvements seen in CP study. Higher doses showed better results. Would love to know what the higher dose is versus the smaller dose.

40:40mins suggesting a cord blood transfusion followed by an MSC booster.

47mins they have over 2000 families on their wait list which is over a years work for them.

If you can’t see hole video on my Facebook please try on YouTube ( I separated in 3 parts):

Part 1:

https://youtu.be/OVAaUpNzCEY

Part 2:

https://youtu.be/RUaxU4Hga_w

Part 3:

https://youtu.be/pmJ6dVlgK3s

And I will put all power points Photos ( sorry not in in order of presentation):

CD14 cells in cord blood that is special and helps repair brain cells from low oxygen in brain or hypoxic injury

About stem cells :

Watch this dr Kurtzberg presentation ( in English from 12 minutes)

https://m.youtube.com/watch?feature=youtu.be&v=IZ7GeQ3mM7M

From the 20:54, Dr Joanne Kurtzberg says It’s the CD14 cells in cord blood that is special and helps repair brain cells from low oxygen in brain or hypoxic injury

And as I know nobody doing yet hole donor cord blood HLA matched exept Duke ( and yet in clinical trails)….

More on Dr Kurtzberg’s presentation of the good monocytes in cord blood cells:

10:38 [Referring to cord blood cells]…and about 10% are a kind of cells called the monocyte. Monocyte in cord blood is unique and it’s the cell that we think is helping patients with cp and autism. And we don’t think it’s helping because it’s engrafting in the brain or turning into neurons or turning into brain cells. We think it’s helping because it puts out chemicals that signal cells that’s already in the brain to repair damage.

human UCB (hUCB) is a complex internal environment rich in a variety of stem/progenitor cell populations, such as hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs), UCB monocytes (including T regulatory cells (Tregs) and monocyte-derived suppressor cells (MDSCs)) and MSCs…etc….

UCB mononuclear/ whole blood cells in the perinatal ischemic and hypoxic brain model can reduce the inflammatory response to treat injury. To evaluate whether transplanted cells relieve neuroinflammation, there are two indicators:

(1) reduce the infiltration of CD4 þ T cells into the brain; and (2) reduce microglial activation.

all UCB cell types except EPCs have CNS immunoregulatory capacity.

Tregs and monocytes are present in the normal body at a considerable level, and are indispensable in the regulation of peripheral and central immune responses.

« Currently, the use of UCB-based interventions for CP is limited as the components of UCB are complex and possess different therapeutic mechanisms. These can be categorized by three aspects: homing and neuroregeneration, trophic factor secretion, and neuroprotective effects. »

https://www.researchgate.net/publication/328690064_A_New_Approach_to_Cerebral_Palsy_Treatment_Discussion_of_the_Effective_Components_of_Umbilical_Cord_Blood_and_its_Mechanisms_of_Action

There are several paper about cord blood CD14+ cells neuroprotective action ( CB Monocytes – CD14+ cells protect brain cells from Oxygen and Glucose Deprivation in Cortex). Even more: cord blood cells contain many neurotrophic factors, which are very important for brain regeneration.

•Brain-derived neurotrophic factor,

Nerve growth factor-

•Neurotrophin-3 –

•Neurotrophin-4 –

•Glial cell-derived neurotrophic factor –

•Cerebral dopamine neurotrophic factor –

•Mesencephalic astrocyte-derived neurotrophic factor

•Pigment epithelium-derived factor.

https://www.researchgate.net/publication/289510468_CD14_human_umbilical_cord_blood_cells_are_essential_for_neurological_recovery_following_MCAO

Latest Duke publication about CD14:

https://cdn.fbsbx.com/v/t59.2708-21/61565783_397700577506188_2233617151242010624_n.pdf/670794.full.pdf?_nc_cat=105&_nc_oc=AQm-qC11yqS79HyUmrkqnToptSZJxSHk4ULPH1L2INIazkDe9vro0UHWF1fubLjHPxE&_nc_ht=cdn.fbsbx.com&oh=094475c2789b013855fecdc8d8bdda6d&oe=5D1B23DB&dl=1

intravenous autologous cord blood therapy for infantile cerebral palsy

I am not sure if you will be interested in this study( the doctor (Arne Jensen )who wrote this first case treatment for boy in Germany after cardiac arrest with autologous cord blood after global hypoxic-ischemic brain damage caused by cardiac arrest followed by a quadriplegic persistent vegetative state.

But still I will post it in case if sombody will need it:

https://www.researchgate.net/profile/Arne_Jensen/publication/259672653_Autologous_Cord_Blood_Therapy_for_Infantile_Cerebral_Palsy_From_Bench_to_Bedside/links/0f31753295ef18d26d000000/Autologous-Cord-Blood-Therapy-for-Infantile-Cerebral-Palsy-From-Bench-to-Bedside.pdf?origin=publication_detail

Conclusions

From an experimental point of view, treatment for acute hypoxic-ischemic brain damage using mononuclear cells

from human umbilical cord blood was shown to be effective, at least in the model that we and others employed. Also, insights in some important aspects regarding potential mechanisms and modes of action involved have been gathered. However, since there is virtually no information neither on the optimum amount of cells needed nor on the ideal timing of transplantation after the insult to be effective, future work should also focus on these clinically important questions.

From a clinical point of view, intravenous autologous cord blood therapy for infantile cerebral palsy is safe, however, based on the preliminary uncontrolled clinical data available, it appears only to be effective in certain cases. It is important to notice that in the majority of uncontrolled cases it was not effective. Future work and ongoing clinical trials primarily must define both the groups of brain disorders responding and the therapeutic window, in which autologous cord blood therapy may be effective, in order to avoid giving false hopes to the patients and their families. Time matters—in several respects.

The Future State of Newborn Stem Cell Banking:

https://www.researchgate.net/publication/330484459_The_Future_State_of_Newborn_Stem_Cell_Banking/fulltext/5c420bf4458515a4c72f8d18/330484459_The_Future_State_of_Newborn_Stem_Cell_Banking.pdf?origin=publication_detail

Ps:

Cp study 2017 ( Duke)

https://lookaside.fbsbx.com/file/CP%20study.pdf?token=AWzYAXfE0seVXuFwhWBr81Gm3CwpcxnuKfrd_BMMwlsq-3o2ZPHWwbvZc97YU-LH5_3iq7XkENHWq2DI-pdY-ccpChLys-i1zx_4-RB4frx6YaZBcF_kmoybNfTcIiXyZbrH-GmNl5RZ1GXrZRFRm3j9YLtyP8YIemNsyr0jBCqbzc__FmWFw2t5JHO0inJfBGA

stem cell and cerebral palsy & autism Duke

You will be very surprised why I put CP and autism together in this article but in fact by reading all clinical researches I found that for stem cells therapy protocols for autism studies they are practically same as for CP studies…..

I will start with this powerful video ( Duke):

https://youtu.be/IZ7GeQ3mM7M

So I went through the attached Dr K lecture on link (in Israel) and its great. Final found evidence that sex of the donor does not impact success. Some key points:

19:32 mins – starts to talk about autism

21:00 mins – when brain cells are shocked, neurons die unless cord blood is added.

22:07 mins – they took out different cells from the cord blood until they identified CD14 as the only one that stopped the cell death.

27:00 mins – dose is important – high dose showed positive effects.

32:20 mins – 25 million/kg is the higher dose (same dose for the leukemia and CP study).

37:50 mins – With the high dose, MRIs showed improved connections in the brain.

41:00 mins – for genetic conditions, need to do chemo to get the new cells to stay in the brain, this is a serious risk. If genetic issue, use someone else’s cells.

45:00 mins – babies born with autism don’t control which pathways turn on and off, some pathways that are supposed to shut down in early infancy, don’t. This includes microglial activation, which causes sensory issues. (this actually matches Nemechek protocol).

46:30 mins – Vineland would usually go backwards over time as severe kids get older, but during the trial, their scores stayed stable.

51:55 mins – trial due to finish in August, with answers released next fall.

1:09 mins – CD14 cells can’t be expanded. Epilepsy shown no improvement in seizures.

1:12 mins – not know yet whether age impacts success.

1:15mins – the 30% of kids that didn’t show vineland improvement, tended to have lower IQs.

1:17mins – no preference seen whether male or female donors are better.

Cp study 2017 ( Duke)

https://lookaside.fbsbx.com/file/CP%20study.pdf?token=AWzYAXfE0seVXuFwhWBr81Gm3CwpcxnuKfrd_BMMwlsq-3o2ZPHWwbvZc97YU-LH5_3iq7XkENHWq2DI-pdY-ccpChLys-i1zx_4-RB4frx6YaZBcF_kmoybNfTcIiXyZbrH-GmNl5RZ1GXrZRFRm3j9YLtyP8YIemNsyr0jBCqbzc__FmWFw2t5JHO0inJfBGA

One more interesting ( but more old video):

https://youtu.be/d4TD2eJV8bA

donor cord blood from a donor cord blood bank ( only Duke in USA :they just starting first trail with donor cord blood with hla matching….there are some others clinics doing donors cord blood but nobody doing hla matching exept Duke) as well they are doing donors MSC first trail for autism in Duke: This is duke trail autism :

https://clinicaltrials.gov/show/NCT03099239

• Donors MSC from cord tissue ( HLA matching no needed) Duke is doing naw MSC expanded from cord tissue as part of ongoing donor trail for CP : Duke donor trail CP: (cord blood and cord tissue expanded MSC):

https://clinicaltrials.gov/ct2/show/NCT03473301?term=Stem+cells&cond=Cp+AND+%22Brain+Injuries%22&rank=4

So for Duke donor trail CP: (cord blood and cord tissue expanded MSC):

https://clinicaltrials.gov/ct2/show/NCT03473301?term=Stem+cells&cond=Cp+AND+%22Brain+Injuries%22&rank=4

So in this CP trail Duke will decide children’s into 3 groups:

Cord blood group

MSc tissue group here what they will recive:

“the « MSC » arm will receive three hCT-MSC infusions, one each at baseline, three months, and six months” and “Cord Tissue Mesenchymal Stromal Cells

Subjects will receive three intravenous infusions of 2×106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors”

And Placebo group ( nothing during first year of trail just at the baseline they will recive stem cells treatment )

Contact for Duke :

Duke will do it outside of trials : expanded access or compassionate care.

( but you need to pay for it… Oh and the fee is 15000$) some USA parents got it covered by insurance but not all of them ( diferent insurances may be -don’t know)

Requires :

1) you have cells banked ( own child stem cells from his birth )

2)you have sibling cells banked that HLA matches your child

3) no prior stem cell treatment

4) no ventilator

5) no trach

6)Based on childs weight- Must have a minimum of 25 million cells per Kilogram stored.

7)Duke also turns down if child had immunosuppressive drugs at all.

Process takes anywhere from 6 months to 1 year to get approved. Must turn in a ton of paperwork, records, scans.

3-4 day process ( presence in Duke) 45min IV in arm one injection.

Duke Stem cells contacts:

https://www.dukehealth.org/treatments/cord-blood-transplant

The objective of the study is to enable access to sibling or autologous umbilical cord blood (UCB) infusions for children with various brain disorders.

The use of UCB in this fashion is based on safety and efficacy data from prior and ongoing clinical trials at Duke University Medical Center in over 700 patients with these diagnoses infused with autologous or sibling UCB over the past decade.

Autism Spectrum Disorder

Autism

Cerebral Palsy

Hydrocephalus

Apraxia of Speech

Hypoxia Ischemia, Cerebral

Drowning; Anoxi

Duke:

Adress:

Pediatric Bone and Marrow Transplant Program at Duke

Joanne Kurtzberg , MD

Durham, NC 27710

401-8002

Duke Linet: 919-668-1119

cordbloodtherapyinfo@dm.duke.edu

Bethany Kister RN

Joanne Kurtzberg, MD

Director, Carolinas Cord Blood Bank

Chief Scientific Officer, Robertson Clinical and Translational Cell Therapy Program

Director, Pediatric Blood and Marrow Transplant Program

DUMC Box 3350

2400 Pratt Street Room #9026

Durham, NC 27705

919-668-1119 (phone)

919-668-7161 (fax)

kurtz001@mc.duke.edu

Dr Kurtzberg in Duke university doing just exceptional research for stem cells forCP children’s and for autism ( and if one day it will be recognized by fda it’s because if duke efforts)

Next to watch I will advice you:

Dr. Kurtzberg’s virtual conference at the World Cord-Blood Day 2018:

Extending Cord Blood to Regenerative Therapies for the Brain: Autism, Cerebral Palsy & Stroke: Dr. Joanne Kurtzberg (Duke Department of Pediatrics)

Dr. Kurtzberg’s research has focused on children with selective inborn errors of metabolism. Her work has shown that cord blood cells, administered intravenously after myeloablative therapy engraft in the brain. In addition, DUOC-01, a cord blood derived cellular therapy that promotes myelination, is undergoing testing to augment standard umbilical cord blood treatment in children with leukodystrophies.  In this presentation, Dr. Kurtzberg will discuss her on-going research using cord blood to potentially treat autism, cerebral palsy and stroke.  She also will explore the potential use of DUOC-1 and highlight the importance of quality control considering the numerous new potential clinical applications of cord blood.

For those that didn’t get the chance to watch it, here’s Dr. Kurtzberg’s virtual conference at the World Cord-Blood Day 2018 that took place on November 15. This link will allow you to bypass the registration process and go directly to the presentation. Once you start watching it, don’t pause or switch apps as you won’t be able to go back (you’ll need to watch the video all over again if you happen to pause.) It takes about 35 minutes to watch the entire presentation. — AND here’s also a link to a separate interview they had with Dr. K :

Interview: https://app.gotowebinar.com/sl/index.html?fbclid=IwAR0igudPXP0xZ2gq-MS9yyaMX-PIlgxBd8Rv2XZNdUOt1ytvpS5EtyZjgv0#/4138639127435702018/387074667558437643

Conference: https://app.gotowebinar.com/sl/index.html?fbclid=IwAR1U_R3OvgNnYgLM6fuL58InfAzp_c7gAAk2a-jGRBP-AC4ZQgqnpeqUqAY#/8722573472398615298/2096575555213456652

you can watch other world renowned experts in the field in this link

https://www.worldcordbloodday.org/video-recordings-world-cord-blood-day-2018.html

Very interesting presentation: ( need to register in order to see and listen):

« “Cord Blood for Traumatic Brain Injury / Neurological Injuries” – Dr. Charles Cox : « Neurological injuries have both a primary and secondary component. The secondary component is mediated, in part, by pro-inflammatory cells from the monocyte/macrophage and microglial lineages. Many cellular therapeutics, cord blood in particular can dampen the hyper-inflammatory response to injury that can be deleterious to ultimate repair and recovery. This presentation will highlight some of the potential mechanisms of action that serve as the background for the use of cord blood for these indications. «

French:

Pour ceux qui n’ont pas eu la chance de le voir, voici la conférence virtuelle du Dr. Kurtzberg à la Journée mondiale du selules souches du cordon umbilical 2018, de 15 novembre. Ce lien vous permettra de contourner le processus d’inscription et d’accéder directement à la présentation . Une fois que vous avez commencé à regarder la vidéo, ne mettez pas les applications en pause ni changez d’application, car vous ne pourrez pas revenir en arrière (vous devrez regarder la vidéo à nouveau si vous faites une pause interview commence dans 2-3 minutes de début) Il faut environ 35 minutes pour regarder la présentation entière. Et voici également un lien vers une interview séparée qu’ils ont eue avec le Dr K:

Interview: https://app.gotowebinar.com/sl/index.html?fbclid=IwAR0igudPXP0xZ2gq-MS9yyaMX-PIlgxBd8Rv2XZNdUOt1ytvpS5EtyZjgv0#/4138639127435702018/387074667558437643

Conference: https://app.gotowebinar.com/sl/index.html?fbclid=IwAR1U_R3OvgNnYgLM6fuL58InfAzp_c7gAAk2a-jGRBP-AC4ZQgqnpeqUqAY#/8722573472398615298/2096575555213456652

« “Extending Cord Blood to Regenerative Therapies for the Brain: Autism, Cerebral Palsy & Stroke” – Dr. Joanne Kurtzberg (Duke Department of Pediatrics, Marcus Center for Cellular Cures): Dr. Kurtzberg’s research has focused on children with selective inborn errors of metabolism. Her work has shown that cord blood cells, administered intravenously after myeloablative therapy engraft in the brain. In addition, DUOC-01, a cord blood derived cellular therapy that promotes myelination, is undergoing testing to augment standard umbilical cord blood treatment in children with leukodystrophies. In this presentation, Dr. Kurtzberg will discuss her on-going research using cord blood to potentially treat autism, cerebral palsy and stroke. She also will explore the potential use of DUOC-1 and highlight the importance of quality control considering the numerous new potential clinical applications of cord blood.« 

Stem cells stroke study ( surgical transplantation)

Stroke victims in the Bay Area are seeing incredible recoveries, some literally overnight, thanks to a new kind of stem cell treatment at Stanford University.

Vidéo:

https://youtu.be/VGuBMroX7c8

Study :

https://clinicaltrials.gov/ct2/show/NCT01287936?term=Stanford+University&cond=Stem+cells+stroke&rank=1

https://med.stanford.edu/news/all-news/2016/06/stem-cells-shown-safe-beneficial-for-chronic-stroke-patients.html

Results:

https://www.ncbi.nlm.nih.gov/m/pubmed/27256670/

Hbot +stem cells together what do we know about ?

Hi everybody I get permission to shere this informations from LEAH RODAS, Administrator and central coordinator for the Center of dr Dr. Richard Neubauer’s ( may be not everybody knows but he is one of first doctors who started to treat neurological conditions with Hbot.) Dr. Neubauer’s pioneering work with hyperbaric oxygen and the potentially recoverable brain led to the development of the first medical center in the world to focus on the role of HBOT in aiding the recovery of patients from stroke, coma, traumatic brain injury, cerebral palsy, and anoxic encephalopathy.

https://en.m.wikipedia.org/wiki/Richard_A_Neubauer?wprov=sfti1

http://www.oceanhbo.com/index.html

This one was one of reference dr Arun Mukherjee was using during his presentation at latest Denver Hbot conference 2018 :

But it was about this study as well: ( part of presentation)

case of study:

About stem cells and Hbot for congenital heart condition :

http://crimsonpublishers.com/didd/pdf/DIDD.000504.pdf

But it’s for carmiopathy case ( so stem cells injections was done near heart zone where located the problem of patient)….

Day 1 lecture 7 Arun Mukherjee:

Stem cells +Hbot ( sorry I can’t openly share this dr Arun Mukherjee PowerPoint presentation ) but you can contact me by my mail and ask privately send it to you.

So here on photos: presentation of : “Stem cells therapy and HBO for brain-injured children and cerebral palsy “ ; J L Diaz – Barbosa & F J Morales; Proc. 3d Int. symp. For CP and the brain-injured child, July 2003, Fort Lauderdale, fl,USA)

I think first : it’s old presentation 2003…. and they where using embryonic stem cells !!!! So honestly this kind of stem cells can grow to teratomas…

But in presentation of dr Arun Mukherjee he is talking about MSC ( if I understood well ? Allogenic Wharton Jelly)

So why he used such kind referral in his 2018 presentation ? With embryonic sheeps cells? For me it’s just incomprehensible….

….